{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-23-000064","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2023-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.842027+00:00","generated_at":"2026-06-13T16:29:17.455173+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Tarsus shareholders elect three Class III directors, ratify E&Y as auditor","bullets":["Andrew Goldberg, Scott Morrison, Wendy Yarno elected to board until 2026 annual meeting.","Director election votes: Goldberg 16.18M for, Morrison 14.67M, Yarno 16.56M; each had 4.98M broker non-votes.","Ratification of Ernst & Young as independent auditor for FY 2023 passed with 22.17M for, 7,065 against.","Annual meeting held June 22, 2023; 22.18M of 26.80M shares represented a quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-23-000064","json":"https://secwatch.observer/filing/0001819790-23-000064.json","markdown":"https://secwatch.observer/filing/0001819790-23-000064.md","text":"https://secwatch.observer/filing/0001819790-23-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000064/0001819790-23-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000064/tars-20230622.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:29:17.455173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4963002a736bdb6eeb9e79376080c6600c029723","claim":"Tarsus Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-22 meeting.","evidence_excerpt":"Our stockholders approved the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000064/0001819790-23-000064-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"},{"claim_id":"9ec44df59a5987df70bae5101cd1176279ecc55a","claim":"Tarsus Pharmaceuticals, Inc. shareholders approved Election of three nominees as Class III directors at the 2023-06-22 meeting.","evidence_excerpt":"The following nominees were elected to serve as Class III directors for a term that will continue until the 2026 annual meeting of stockholders or until their respective successors have been duly elected and qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000064/0001819790-23-000064-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}